Posted by Michael Wonder on 06 Feb 2018
Quebec adds Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
5 February 2018 - Erelzi has been added to the Quebec Drug Insurance Plan based on specific criteria for the treatment of moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active ankylosing spondylitis.
Quebec is the most recent province to have added Erelzi (etanercept) 50 mg to its formulary of exception drugs covered by the province's Public Prescription Drug Insurance Plan for the treatment of multiple inflammatory diseases.
The provincial listing has been in effect since 1 February 2018. Sandoz was granted Health Canada approval for Erelzi in April 2017 and Sandoz Canada launched the biosimilar in Canada in August 2017.
